abstract |
The present disclosure relates to anti-Claudin18.2 antibodies and uses thereof. Specifically, the present invention relates to an anti-Claudin18.2 antibody; murine antibodies, chimeric antibodies, humanized antibodies and antigen-binding fragments thereof comprising the CDRs of the anti-Claudin18.2 antibody, and their use as medicines. In particular, the present disclosure relates to the use of an anti-Claudin18.2 antibody in the preparation of a medicament for treating a Claudin18.2-positive disease or disorder. |